Positive Lexeo Therapeutics, Inc. interim data from SUNRISE-FA study highlights LX2006's potential for Friedreich's Ataxia.

NICE is unable to make a recommendation about the use in the NHS of omaveloxolone for treating Friedreich's ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission.

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) to treat Friedreich's ataxia in ...

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first treatment for patients aged 16 years and older with the rare ...

Huge numbers of Brits could be driving without having notified the DVLA about their pre-existing conditions that should be ...

UK MHRA grants marketing authorisation to Biogen’s omaveloxolone to treat Friedreich’s ataxia: United Kingdom Friday, April 25, 2025, 12:00 Hrs [IST] The Medicines and Healthc ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

The simple test is something most of us should be able to do, and if not, it might be best to get checked out.